RB Capital Management LLC Reduces Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

RB Capital Management LLC lessened its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,626 shares of the medical equipment provider’s stock after selling 71 shares during the period. RB Capital Management LLC’s holdings in Intuitive Surgical were worth $549,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brookstone Capital Management grew its position in Intuitive Surgical by 277.7% in the third quarter. Brookstone Capital Management now owns 7,259 shares of the medical equipment provider’s stock worth $1,985,000 after acquiring an additional 5,337 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Intuitive Surgical by 10.9% during the third quarter. Commonwealth Equity Services LLC now owns 61,148 shares of the medical equipment provider’s stock worth $17,873,000 after purchasing an additional 6,018 shares during the period. Vicus Capital acquired a new stake in Intuitive Surgical during the 3rd quarter worth $263,000. Cambridge Investment Research Advisors Inc. lifted its position in Intuitive Surgical by 15.1% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 27,295 shares of the medical equipment provider’s stock valued at $7,978,000 after acquiring an additional 3,589 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC bought a new stake in Intuitive Surgical in the 3rd quarter valued at approximately $907,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Trading Up 0.3 %

Shares of Intuitive Surgical stock traded up $1.08 during midday trading on Wednesday, reaching $371.70. The company had a trading volume of 941,461 shares, compared to its average volume of 1,636,208. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76. The stock has a fifty day simple moving average of $385.96 and a 200 day simple moving average of $348.19. The company has a market capitalization of $131.84 billion, a price-to-earnings ratio of 66.90, a price-to-earnings-growth ratio of 4.83 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter last year, the firm earned $1.00 earnings per share. The company’s revenue was up 11.5% on a year-over-year basis. Sell-side analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Wall Street Analyst Weigh In

ISRG has been the topic of a number of analyst reports. Truist Financial boosted their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. Citigroup increased their price objective on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Wells Fargo & Company upped their target price on Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research note on Friday, January 19th. Finally, Jefferies Financial Group boosted their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research note on Friday, April 19th. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $396.17.

Insider Activity at Intuitive Surgical

In related news, EVP Robert Desantis sold 20,296 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the completion of the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at $2,168,656.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, SVP Mark Brosius sold 196 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the sale, the senior vice president now owns 1,842 shares in the company, valued at approximately $736,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Robert Desantis sold 20,296 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $393.80, for a total value of $7,992,564.80. Following the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The disclosure for this sale can be found here. In the last three months, insiders sold 226,967 shares of company stock valued at $87,848,586. 0.90% of the stock is owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.